Your browser doesn't support javascript.
loading
A Real-World Assessment of Stage I Lung Cancer Through Electronic Nose Technology.
Rocco, Gaetano; Pennazza, Giorgio; Tan, Kay See; Vanstraelen, Stijn; Santonico, Marco; Corba, Robert J; Park, Bernard J; Sihag, Smita; Bott, Matthew J; Crucitti, Pierfilippo; Isbell, James M; Ginsberg, Michelle S; Weiss, Hallie; Incalzi, Raffaele Antonelli; Finamore, Panaiotis; Longo, Filippo; Zompanti, Alessandro; Grasso, Simone; Solomon, Stephen B; Vincent, Alain; McKnight, Alexa; Cirelli, Michael; Voli, Carmela; Kelly, Susan; Merone, Mario; Molena, Daniela; Gray, Katherine; Huang, James; Rusch, Valerie W; Bains, Manjit S; Downey, Robert J; Adusumilli, Prasad S; Jones, David R.
Afiliación
  • Rocco G; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York; Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: roccog@mskcc.org.
  • Pennazza G; Department of Engineering, Unit of Electronics for Sensor Systems, Università Campus Bio-Medico di Roma, Rome, Italy.
  • Tan KS; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Vanstraelen S; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Santonico M; Department of Science and Technology for Sustainable Development and One Health, Unit of Electronics for Sensor Systems, Università Campus Bio-Medico di Roma, Rome, Italy.
  • Corba RJ; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Park BJ; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Sihag S; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Bott MJ; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Crucitti P; Department of Thoracic Surgery, Università Campus Bio-Medico di Roma, Rome, Italy.
  • Isbell JM; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Ginsberg MS; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Weiss H; Department of Anesthesiology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Incalzi RA; Department of Geriatrics, Research Unit of Internal Medicine, Università Campus Bio-Medico di Roma, Rome, Italy.
  • Finamore P; Department of Thoracic Surgery, Università Campus Bio-Medico di Roma, Rome, Italy.
  • Longo F; Department of Thoracic Surgery, Università Campus Bio-Medico di Roma, Rome, Italy.
  • Zompanti A; Department of Engineering, Unit of Electronics for Sensor Systems, Università Campus Bio-Medico di Roma, Rome, Italy.
  • Grasso S; Department of Science and Technology for Sustainable Development and One Health, Unit of Electronics for Sensor Systems, Università Campus Bio-Medico di Roma, Rome, Italy.
  • Solomon SB; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Vincent A; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • McKnight A; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Cirelli M; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Voli C; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Kelly S; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Merone M; Department of Engineering, Unit of Computational Systems and Bioinformatics, Università Campus Bio-Medico di Roma, Rome, Italy.
  • Molena D; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Gray K; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Huang J; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Rusch VW; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Bains MS; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Downey RJ; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Adusumilli PS; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Jones DR; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York; Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York.
J Thorac Oncol ; 2024 May 16.
Article en En | MEDLINE | ID: mdl-38762120
ABSTRACT

INTRODUCTION:

Electronic nose (E-nose) technology has reported excellent sensitivity and specificity in the setting of lung cancer screening. However, the performance of E-nose specifically for early-stage tumors remains unclear. Therefore, the aim of our study was to assess the diagnostic performance of E-nose technology in clinical stage I lung cancer.

METHODS:

This phase IIc trial (NCT04734145) included patients diagnosed with a single greater than or equal to 50% solid stage I nodule. Exhalates were prospectively collected from January 2020 to August 2023. Blinded bioengineers analyzed the exhalates, using E-nose technology to determine the probability of malignancy. Patients were stratified into three risk groups (low-risk, [<0.2]; moderate-risk, [≥0.2-0.7]; high-risk, [≥0.7]). The primary outcome was the diagnostic performance of E-nose versus histopathology (accuracy and F1 score). The secondary outcome was the clinical performance of the E-nose versus clinicoradiological prediction models.

RESULTS:

Based on the predefined cutoff (<0.20), E-nose agreed with histopathologic results in 86% of cases, achieving an F1 score of 92.5%, based on 86 true positives, two false negatives, and 12 false positives (n = 100). E-nose would refer fewer patients with malignant nodules to observation (low-risk 2 versus 9 and 11, respectively; p = 0.028 and p = 0.011) than would the Swensen and Brock models and more patients with malignant nodules to treatment without biopsy (high-risk 27 versus 19 and 6, respectively; p = 0.057 and p < 0.001).

CONCLUSIONS:

In the setting of clinical stage I lung cancer, E-nose agrees well with histopathology. Accordingly, E-nose technology can be used in addition to imaging or as part of a "multiomics" platform.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Thorac Oncol Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Thorac Oncol Año: 2024 Tipo del documento: Article
...